BUILD 3: Bosentan Use in Interstitial Lung Disease

Update Il y a 3 ans
Reference: NCT00391443

Woman and Man


BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.

Inclusion criteria

  • Idiopathic pulmonary fibrosis